

研究人員中文網頁資料表

姓名:	余文鍾	填表日期:	2020/05/29	
單位:	內科部 心臟內科	現職職稱:	主治醫師	
Email:	wcyu@ghtpe.gov.tw	連絡電話:	02-28712121 #2997	
學歷:	國立陽明醫學院 醫學系 學士			
重要經歷:	<p>2011/02 - 迄今 國立陽明大學 內科 副教授</p> <p>2007/12至2008/11 Johns Hopkins University School of Medicine, Department of Medicine post-doctoral fellow</p> <p>2002/08至2011/01 國立陽明大學 內科 助理教授</p> <p>1998/07至2012/06</p> <p style="margin-left: 2em;">臺北榮民總醫院 內科部 心臟內科</p> <p style="margin-left: 2em;">內科部心臟科 主治醫師且兼任國立陽明大學內科副教授</p> <p>1997/08至2002/07 陽明大學 內科系 講師</p> <p>1996/07至1998/06 臺北榮總 心臟內科 總醫師</p> <p>1995/07至1996/05 臺北榮民總醫院 心臟 內科 住院醫師</p> <p>1992/07至1995/06 臺北榮民總醫院 內科部 住院醫師</p>			
研究方向: (關鍵詞)	1. 心臟內科 2. 心臟血管影像 3. 心肌病變			
五年內 代表著作:	<p>Hsu MJ, Chang FP, Lu YH, Hung SC, Wang YC, Yang AH, Lee HJ, Sung SH, Wang YF, Yu WC, Hsu TR, Huang PH, Chang SK, Dzhagalov I, Hsu CL, Niu DM. (2018, Jun). Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients. <i>Genet Med.</i> (SCI, 8/171).</p> <p>Chien, Y. Chou, S. J. Chang, Y. L. Leu, H. B. Yang, Y. P. Tsai, P. H. Lai, Y. H. Chen, K. H. Chang, W. C. Sung, S. H. Yu, W. C. (2018, May). Inhibition of arachidonate 12/15-lipoxygenase improves alpha-galactosidase efficacy in iPSC-derived cardiomyocytes from Fabry Patients. <i>Int J Mol Sci.</i> 19(5):1480. (SCI, 70/292). MOST 106-2314-B-075-059. 本人為通訊作者.</p> <p>Kuan-Hsuan Chen, Yueh-Ching Chou, Chen-Yuan Hsiao, Yueh Chien, Kang-Ling Wang, Ying-Hsiu Lai, Yuh-Lih Chang, Dau-Ming Niu, Wen-Chung Yu* (2017, Apr). Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy. <i>Biochemical and Biophysical Research Communications</i>, 486 (2):293-299. 本人為通訊作者</p>			

	<p>Tseng WL, Chou SJ, Chiang HC, Wang ML, Chien CS, Chen KH, Leu HB, Wang CY, Chang YL, Liu YY, Jong YJ, Lin SJ, Chiou SH, Yu WC*, Lin SZ. (2017, Mar). Imbalanced production of reactive oxygen species and mitochondrial antioxidant-SOD2 in Fabry disease-specific human induced pluripotent stem cell-differentiated vascular endothelial cells. <i>Cell Transplant</i>, 26(3):513-527. (SCI, 34/124). 本人為通訊作者</p> <p>Lee, H. J. Hsu, T. R. Hung, S. C. Yu, W. C. Chu, T. H. Yang, C. F. Bizjajeva, S. Tiu, C. M. Niu, D. M. (2017, Feb). A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation. <i>BMC Neurol</i>, 17 (1): 25.</p> <p>Ting-Rong Hsu, Fu-Pang Chang, Tzu-Hung Chu, Shih-Hsien Sung, Svetlana Bizjajeva, Wen-Chung Yu*, Dau-Ming Niu* (2017, Jan). Comparison of the results of endomyocardial biopsies and cardiac manifestations in Taiwanese patients with the Chinese hotspot IVS4+919G>A mutation: data from the Fabry Outcome survey. <i>INT J MOL SCI</i>, 18(1). pii: E119. (SCI). 本人為通訊作者.</p> <p>Hsu TR, Hung SC, Chang FP, Yu WC, Sung SH, Hsu CL, Dzhagalov I, Yang CF, Chu TH, Lee HJ, Lu YH, Chang SK, Liao HC, Lin HY, Liao TC, Lee PC, Li HY, Yang AH, Ho HC, Chiang CC, Lin CY, Desnick RJ, Niu DM. (2016, Dec). Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation. <i>J Am Coll Cardiol</i> , 68(23):2554-2563. (SCI, 1/124).</p> <p>Song HY, Chiang HC, Tseng WL, Wu P, Chien CS, Leu HB, Yang YP, Wang ML, Jong YJ, Chen CH, Yu WC*, Chiou SH. (2016, Dec). Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease. <i>Int J Mol Sci.</i> , 17(12). pii: E2089.. (SCI, 52/163). MOST 104-2633-B-009-003. 本人為通訊作者.</p> <p>Chien Y, Chien CS, Chiang HC, Huang WL, Chou SJ, Chang WC, Chang YL, Leu HB, Chen KH, Wang KL, Lai YH, Liu YY, Lu KH, Li HY, Sung YJ, Jong YJ, Chen YJ, Chen CH, Yu WC*. (2016, Nov). Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation. <i>Oncotarget</i>. (SCI, 36/213). 本人為通訊作者.</p> <p>Chen K-H, Chien Y, Wang K-L, Leu H-B, Hsiao C-Y, Lai Y-H, Wang C-Y, Chang Y-L, Lin S-J, Niu D-M, Chiou S-H, Yu W-C*. (2016, Oct). Evaluation of pro-inflammatory prognostic biomarkers for fabry cardiomyopathy with enzyme replacement therapy. . <i>Canadian Journal of Cardiology</i>., 32(10):1221.e1-1221.e9. (SCI, 36/124). 本人為通訊作者</p> <p>Lu DY, Wang KL, Chen CK, Yu WC*. (2016, Aug). A ring in heart.. <i>Eur Heart J.</i>, 37(31):2501. (SCI, 3/124). 本人為通訊作者.</p>
研究室成員:	宋思賢 廖若男 黃偉銘 李慶威 陳素真 楊妤柔 楊宛逸

*本表敬請精要填寫，內容限二頁內。